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Graft-Versus-Leukemia Effect of Donor Lymphocyte Transfusions in 
Marrow Grafted Patients
By Hans-Jochem Kolb, Anton Schattenberg, John M. Goldman, Bernd Hertenstein, Niels Jacobsen, William Arcese, 
Per Ljungman, Augustin Ferrant, Leo Verdonck, Dietger Niederwieser, Frits van Rhee, Johann Mittermueller, 
Theo de Witte, Ernst Holler, and Hassan Ansari for the European Group for Blood and Marrow Transplantation
Working Party Chronic Leukemia
The immune reactivity of allogeneic lymphocytes plays a 
major role in the control of leukemia after bone marrow 
transplantation. In patients with recurrent leukemia after 
marrow transplantation, chimerism and tolerance provide 
ideal conditions for adoptive immunotherapy with donor 
lymphocytes. We studied the effect of donor lymphocyte 
transfusions on acute and chronic leukemia in relapse after 
bone marrow transplantation. One hundred thirty-five pa­
tients with chronic myeloid leukemia (CML) (N = 84), acute 
myeloid leukemia (AML) (N =  23), acute lymphoblastic leuke­
mia (ALL) (N = 22), myelodysplastic syndrome (MDS) (INI = 
5), and polycythemia vera with osteomyelofibrosis (PCV) (N 
= 1) were treated with transfusions of donor lymphocytes. 
Patients were monitored for response of leukemia, including 
in CML, the use of the polymerase chain reaction for bcr/abl 
mRNA transcripts and for the occurrence of graft-versus- 
host disease (GVHD) and myelosuppression. Complete re­
missions were induced by donor lymphocyte transfusions
in 54 patients with CML (73%) and in the patient with PCV; 
complete remissions were also induced in five patients (29%) 
with AML and a patient with MDS. In contrast, ALL did not 
respond to adoptive immunotherapy with donor lympho­
cyte transfusions. Remissions were durable in patients 
treated for CML in chronic phase (probability of remission: 
87% at 3 years). Lymphocyte transfusions were also given 
to 18 patients with ALL, AML, MDS, and transformed phase 
CML who were in remission after chemotherapy. These re­
missions were not durable. Fifty-two patients (41%) devel­
oped GVHD of grade 2 or more, and 41 patients (34%) 
showed signs of myelosuppression. Seventeen patients died 
without leukemia, 14 patients with GVHD and/or myelosup­
pression. Donor lymphocyte transfusions exert strong ef­
fects against myeloid forms of leukemia and induce durable 
remissions in CML.
© 1995 by The American Society of Hematology.
HE ROLE OF ALLOGENEIC lymphocytes in the eradi­
cation of leukemia is well established. In mice, trans­
plantation of allogeneic bone marrow eliminated leukemia, 
and transplantation of marrow from syngeneic donors failed.1 
Allogeneic marrow transplantation as a form of adoptive 
immunotherapy of leukemia was limited by the inevitable 
occurrence of graft-versus-host disease (GVI-ID).2 
with GVHD had fewer relapses than patients without GVHD, 
but only patients with mild degrees of GVHD had a survival 
advantage/ T lymphocytes are most probably responsible 
for GVHD and the graft-versus-leukemia (GVL) effect; 
depletion of T lymphocytes decreased the incidence and se­
verity of GVHD, but increased the risk of relapse.4,5 How­
ever, a beneficial effect of adding T lymphocytes early after 
transplantation on high-risk leukemia could not be shown. 
Transfusion of donor lymphocytes early after transplantation 
increased the incidence and severity of acute GVHD without 
improving the control of leukemia.*’ A possible solution of 
the dilemma between the risk of GVHD and the benelil of 
a GVL effect was sought in delaying the transfusion of donor 
lymphocytes to a time when GVH tolerance was established. 
In canine chimeras, the delay of the transfusion for 2 months 
or longer after transplantation prevented acute GVHD without 
abrogating the beneficial effect on chimerism and the transfer 
of immunity.7 Indeed, the first patients treated with transfusion 
of donor lymphocytes showed only mild or no GVHD.K
In the meantime, we" and others4' 15 have shown that remis­
sions can be induced in patients with chronic myelogenous 
leukemia (CML) in relapse after marrow transplantation by 
the transfusion of lymphocytes from the marrow donor with­
out chemo or radiotherapy. Occasional patients with acute 
myeloid leukemia (AML) have benefited from donor lym­
phocyte transfusions,16 but in general, the response of differ­
ent types of leukemia to the GVL effects of donor lympho­
cyte transfusions is not known. Here we review the results
reported by 27 transplant centers in the European Group for 
Blood and Marrow Transplantation (EBMT) and evaluate 
the risks and benefits of donor lymphocyte transfusions in 
patients with recurrent CML in various stages, AML, acute 
lymphoblastic leukemia (ALL), myelodysplastic syndrome 
(MDS), and polycythemia vera (PCV).
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MATERIALS A N D  M ETHODS
Data collection. Centers for bone marrow transplantation partic­
ipating in tiie European Group for Blood and Marrow Transplanta­
tion (EBMT) were asked to report their experience with donor lym­
phocyte transfusions for the treatment of recurrent leukemia after 
marrow transplantation. Between May 1992 and May 1994. we re­
ceived reports on 140 treatment episodes in 135 patients from 27 
centers. Attempts were made to prevent selective reporting of favor­
able cases. Centers were asked to report all sequentially treated 
patients, and the results were discussed with each center.
The reports included data on age and sex of the patients and their 
donors, diagnosis and stage of the disease at the time of transplanta­
tion, histocompatibility and relationship of the donor, date of trans­
plant, conditioning regimen, method of prophylaxis of GVHD, sever­
ity of acute and chronic GVHD, as well as other major complications 
after transplantation, time of relapse, leukocyte count and the per­
centage of blasts, cytogenetic data on the percentage of Philadelphia- 
positive metaphases and other karyotype abnormalities, presence of 
GVHD and evidence of chimerism at the time of leukemic relapse, 
and in case of CML, the type of relapse, ie, cytogenetic, hematologic, 
or in transformation. Treatment related information included details 
of chemotherapy, the dates of administration and response, details 
of treatment with interferon-« and clinical, as well as cytogenetic 
response, date and number of days with lymphocyte transfusions, 
number of mononuclear cells transfused, and the response to the 
transfusion. The outcome of the treatment was assessed by: (I) 
severity of GVHD, involvement of skin, liver and gut; (2) leukope­
nia, thrombocytopenia, and reticulocytopema secondary to the lym­
phocyte transfusion and unrelated to chemotherapy; (3) response of 
the leukemia including karyotype analyses and reverse transcriptase 
polymerase chain reactions of bcr/abl c-DNA. Survival, causes of 
morbidity and death, and recurrence of leukemia after lymphocyte 
transfusions were also evaluated.
Patients. The patients’ characteristics are summarized in Table
I. Eighty-four patients were treated for recurrent CML. I patient for 
PCV, 23 patients for AML, 5 patients for MDS, and 22 patients for 
ALL,. The median age of both the patients and the donors was 35 
years. One hundred seventeen patients had an HLA-identical sibling 
donor, 11 patients had an unrelated donor, in 6 patienLs the donor 
was mismatched for one HLA-antigen, and 1 patient had a monozy­
gotic twin donor.
Definitions. Relapse of leukemia was delined as the recurrence 
of signs and symptoms of leukemia including cytogenetic evidence. 
In CML., cytogenetic relapse was defined as the recurrence of meta­
phases with the Philadelphia-ehromosome without hematologic or 
clinical features of CML. Hematologic relapse is the recurrence 
of CML with the characteristics of chronic phase disease, whereas 
transformed relapse is the recurrence with the characteristics of ac­
celerated or blastic phase. Blastie phase is defined as an increase of 
blasts in marrow to 30% or more and/or in blood to 20% or more. 
Accelerated phase is delined as an increase of blasts, eosinophils, 
and basophils unresponsive to conventional chemotherapy not ful­
filling the criteria of blast phase. In PCV, relapse was delined as 
recurrence of host hematopoiesis with leukocytosis and thrombo-
Complete remission was delined as the absence of signs or symp­
toms of leukemia and the return of normal blood counts and bone 
marrow cel hilarity in the absence of antileukemic therapy. In CML, 
a negative reverse transcriptase polymerase chain reaction (RT-PCR) 
for bcrlabl transcripts17 in marrow or blood and/or the absence of 
metaphases with the Philadelphia chromosome was necessary for 
confirmation. Initially only cytogenetic results were available," until 
more recent RT-PCR was established as a standard method. Re­
sponse was evaluable in patients who survived at least 30 days 
after lymphocyte transfusions because the earliest responses were 
observed 4 weeks after treatment.
Leukocytopenia and thrombocytopenia unrelated to chemotherapy 
did not contradict the definition of complete remission based on RT- 
PCR and cytogenetic results, because they may occur in the course 
of a GVL reaction.
Cytopenia caused by marrow aplasia was observed in some pa­
tients I or 2 months after lymphocyte transfusion. Myelosuppression 
was defined as a hypocellular marrow with the decrease of leukocyte 
counts below 1.0 g/L and/or platelet counts below 20 g/L and/or 
reticulocyte counts below 0.2%.
GVHD was staged clinically according to the criteria described 
by Glucksberg et al.lH
Lymphocyte transfusions. Lymphocyte concentrates were col­
lected from the donor as buffy coat preparations enriched in mononu­
clear cells using cell separators. Collections were performed on one 
or more occasions within 1 or 2 weeks. Between 0.1 and 15 X  10s 
mononuclear cells were transfused per kilogram of body weight 
(Table 1). Nine patients were given infusions of increasing numbers 
of cells over several weeks. Four patients with CML and one patient 
with ALL received several courses of treatment. In these patients 
only the first course was evaluated.
Statistical analysis. The response data were initially analyzed 
by two-by-k chi-square contingency analysis with k equal to the 
number of groups. If P  values were .2, the variables were evalu­
ated in a stepwise logistic regression analysis.
Survival time and duration of remissions were evaluated by 
Kaplan-Meier curves and comparisons between these groups were 
made by log-rank tests. P  values <  .05 were considered statistically 
significant.
RESULTS
Response to donor lymphocyte transfusions. Complete 
hematologic and cytogenetic remission was achieved in 54 
of 75 evaluable patients with CML and in the patient with 
PCV. In CML, remissions were confirmed by the absence 
of bcr/abl-RNA  transcripts in 42 of the 44 patients studied 
using PCR analysis. Complete remissions were induced in 
5 of 17 patients with AML and in 1 of 4 patients with 
MDS who had either not responded or who had not received 
intensive chemotherapy before donor lymphocyte transfu­
sions. However, no remissions were induced in 12 patients 
with ALL who had failed to respond to intensive chemother­
apy or in patients who received donor lymphocyte transfu­
sions as sole therapy (Table 2).
Donor lymphocytes were transfused for consolidation of 
chemotherapy-induced remission in 9 patients with ALL, 4 
patients with AML, a patient with MDS, and 4 patients with 
CML in transformed phase (Table 3). Donor lymphocyte 
transfusions failed to sustain remissions in 6 of 9 patients 
with ALL, 2 of 4 patients with AML, and 2 of 4 patients 
with CML in transformed phase.
Remissions were durable in patients treated in cytogenetic 
and hematologic relapse of CML and in the patient with 
PCV. Only 3 of 54 patients treated in chronic phase and 3 
of 5 patients treated in transformed phase relapsed. After 
lymphocyte transfusion, the probability of relapse for pa­
tients treated in cytogenetic and hematologic relapse was 
less than 20%, and for patients treated in transformed phase
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Table 1. Characteristics of Patients at the Time of Donor Lymphocyte Transfusion
Diagnoses
CML PCV AML MDS ALL
Total no. treated 84 1 23 5 22
No. of male/female patients 50/34 1/0 9/13 2/3 14/8
Median age yrs (range) 36.5 50.3 36.6 39.9 21.5
(4.3-55.2) — (4-54) (8.8-55.3) (8.1-42.8)
Stage at the time of marrow transplantation chronic phase: 67 NA CR 1: 17 NA CR1: 9
accel. phase: 14 ------------ CR 2: 2 — CR2: 5
blastic phase: 3 ------------ >CR 2: 4 >CR2: 8
No. of male/female donors 57/27 0/1 20/3 1/4 10/12
Relationship to the donor
No, of sibling donors 74 1 21 4 21
No. of parental donors 2 ------------- — — -----------
No. of twin donors 1 ------------ — — — ---------- »
No. of unrelated donors 7 ------------ 2 1 1
Histocompatibility of the donor
HLA-identical 77 1 22 5 22
H LA-different 6 ------------ 1 — -----------
Syngeneic 1 — —
Remission duration after BMT in days 726 1/331 237 362 240
median (range) (33-3,288) — (129-1,009) (162-647) (52-1,518)
Time from relapse until lymphocyte 141 47 21 137 53
transfusion in days median (range) (1-1,982) — (1-317) (41-313) (7-852)
No. of mononuclear marrow cells
transfused x  108 per kg body weight 3.0 3.5 2.4 7.6 2.9
(median-range) (0.25-12.3) — (0.1-7.83) (4-15) (0.3-11)
Abbreviations: CML, chronic myelogenous leukemia; PV, polycythemia vera; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; 
ALL, acute lymphoblastic leukemia; NA, not applicable.
it was 100% (Fig I). Remissions were longer in patients 
with AML or MDS than in patients with ALL (Fig 2).
Ten patients had unrelated HLA-identical donors, and 6 
of 8 evaluable patients responded to donor lymphocyte trans­
fusions. A patient with Philadelphia-negative CML was 
treated with lymphocyte transfusions from his monozygotic 
twin brother without success.
Table 2. Response of Chronic and Acute Leukemia to the 
Treatment With Donor Lymphocyte Transfusions
Diagnosis
No. of Patients
Studied Evaluable* Complete Remission (%)
CML
Cytogen relapse 17 17 14 (82)
Hematologic relapse 53 50 39 (78)
Transformed phase 14 8 1 (12.5)
Polycythemia vera 1 1 1
AML 23 17 5 (29)
MDS 5 4 1 (25)
ALL 22 12 0
Total 135 109 61 (56)
Fisher's exact test CML/polycythemia vera versus AML/MDS/ALL: 
P <  .000001; CML cytogenetic/hematologic relapse versus trans­
formed: P -  .0015, AML/MDS versus ALL: P ~ .049.
*  Patients in remission after chemotherapy and patients surviving 
less than 30 days after transfusion were excluded from evaluation.
Survival and complications o f  treatment. The probability
of survival at 2 years is 67% for patients with CML/PCY. 
The median survival time is 248 days for patients with AML/ 
MDS and 132 days for patients with ALL (Fig 3). Sixty- 
four patients died after treatment with lymphocyte transfu­
sions, 47 patients with recurrent leukemia, and 17 patients 
in remission. Six patients died with myelosuppression, 4 
with GVHD and 4 with the combination of GVHD and 
myelosuppression (Table 4). The actuarial probability of 
death in remission at 1 year was: 10% in AML/MDS, 5% 
in ALL, and 18% in CML/PCV.
GVHD occurred in 79 of 133 patients (59%) requiring 
treatment in 55 patients (41%). Myelosuppression is a com­
plication of donor lymphocyte transfusion observed in pa­
tients not treated with chemotherapy. Myelosuppression was 
rare in patients with cytogenetic relapse of CML (2 of 15) 
and in chemotherapy-induced remission (2 of 18); it was 
frequent in hematologic relapse of CML (25 of 50) (P = 
.01). In 5 patients, myelosuppression was corrected by the 
infusion of donor marrow without prior immune suppression; 
30 patients recovered spontaneously.
Pretreatment factors influencing the response. Pretreat­
ment factors related to the transplant center, the patient, its 
disease, type of the donor, the transplant procedure, the type, 
and the treatment of relapse were evaluated for their influ­
ence on response (Table 5). Patients with CML/PV and pa­
tients with diseases other than CML/PV were analyzed sepa­
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Table 3. Remissions After Lymphocyte Transfusion With and Without Prior Chemotherapy for Induction
1
Diagnosis Reported Evaluable
Treated With 
Induction 
Chemotherapy
No, of Patients
Achieving CR After 
Chemotherapy
Achieving CR 
After Lymphocyte 
Transfusion Leukemia-free Survival (d)
ALL 22 21 Yes: 17 Yes: 9 ------------- 21, 70*, 77, 132, 161*, 200,
255, 298*, 442
No: 8 0
No: 4 — 0
AML 23 21 Yes: 8 Yes: 4 — 68, 159t, 201*, 324
No: 4 2 128*, 977
No: 13 — 3 118*, 386*, 855*
MDS 5 5 Yes: 1 Yes: 1 — 325*
No: 4 — 1 244
CML transformed phase 14 12 Yes: 9 Yes: 8* — 118*, 139*, 149, 220
No: 4 0
No: 3 — 1 180
Abbreviation: CR, complete remission.
* Patient alive and in remission, 
t  Patient died of sepsis.
i  One patient showed evidence of relapse at the time of transfusion (day 42).
rately, as the response to donor lymphocyte transfusions was 
significantly better in CML/PV (P <  .00001). In patients 
with diseases other than CML/PV significance of any pre­
treatment factor could not be shown.
In CML, the type of relapse was related to the stage of 
the disease at the time of transplantation: of 17 patients 
treated for cytogenetic relapse, 16 had received transplants 
in chronic phase and 1 patient in accelerated phase; of 54 
patients treated in hematologic relapse, 44 had received 
transplants in chronic phase, and 10 had received transplants
In univariate analysis, the stage of disease at the time of 
transplantation, and the type of relapse, transformed versus 
chronic phase, as defined by cytogenetic or hematologic cri­
teria, had the strongest influence on the response to donor 
lymphocyte transfusions (Table 5). Depletion of T cells from 
the graft and absence of GVHD after bone marrow trans­
plantation were favorable for a response to donor lympho­
cyte transfusions. The number of lymphocytes transfused 
and the use of interferon-a had no influence on the response. 
In a stepwise logistic regression analysis, the type of relapse
in accelerated phase; of 14 patients treated for relapse in and the occurrence of GVHD after marrow transplantation 
transformed phase, 8 had received transplants in chronic were the independent prognostic factors.
phase, 3 in accelerated phase, and 3 in blastic phase. Remis- GVHD, myelosuppression , and their correlation to dis-
sions were not achieved in patients who had received trans- ease response. GVHD and myelosuppression are the major
plants in blastic phase. complications of donor lymphocyte transfusions. Their role
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Fig 2. Cumulative percentage probability of leu­
kemic relapse after lymphocyte transfusions for re­
current acute leukemia. ALL denotes acute lymphob­
lastic leukemia; AML, acute myelogenous leukemia; 
and MDS, myelodysplastic syndrome. Tick marks in­
dicate censored patients.
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in the GVL reaction remains to be defined. Symptoms of 
GVHD developed in 79 of 133 patients (59%); GVHD of 
grade II or greater developed in 55 patients (41%). GVHD 
was more frequent in patients with CML/PV than in patients 
with other diagnoses, but this difference was not significant 
after adjustment of other factors (Table 6). The occurrence 
did not depend on whether the patient had developed GVHD 
after marrow transplantation or on the number of lympho­
cytes transfused. Depletion of T cells from the original mar­
row transplant and treatment with interferon-a before or 
simultaneously with the lymphocyte transfusions were sig­
nificant risk factors for the development of GVHD after 
donor lymphocyte transfusions. An effect of the treatment 
with interferon-a was observed in patients with diagnoses 
other than CML/PV; it was absent in patients with CML/ 
PV. Patients in remission after chemotherapy developed less
GVHD after lymphocyte transfusion. This influence was 
only seen after adjustment for other factors that were signifi­
cant in the univariate analysis. Myelosuppression was ob­
served in patients with predominant hematopoiesis of host 
type. Patients with donor type hematopoiesis—patients in 
chemotherapy-induced remission (2 of 19) and patients with 
cytogenetic relapse of CML (2 of 15)— were less prone to 
myelosuppression than patients in hematologic relapse of
CML (25 of 50) (P <  .008).
The correlation of response with the development of 
GVHD and myelosuppression was studied in patients with 
CML (Table 7). For diseases other than CML, the number 
of patients given donor lymphocyte transfusions as sole ther­
apy was too small for evaluation. CML patients with any 
evidence of GVHD, myelosuppression, or both had a high 
response rate (42 of 46: 91%). Conversely, the response of
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Fig 3. Kaplan-Meier estimate of survival in pa­
tients with recurrent leukemia after bone marrow 
transplantation and treatment with transfusion of 
donor lymphocytes. CML denotes chronic myeloge­
nous leukemia; PCV, polycythemia vera; AML, acute 
® myelogenous leukemia; MDS, myelodysplastic syn­
drome; and ALL, acute lymphoblastic leukemia. Tick 
marks indicate censored patients.
2046 KOLB ET AL
Table 4. Causes of Death After Donor Lymphocyte Transfusions for
Recurrent Leukemia in Marrow Transplanted Patients
therapy complete chimerism is reestablished.8 Severe myelo­
suppression may develop in responding patients. Myelosup­
pression is best explained by a direct effect of the transfused 
lymphocytes on hematopoietic cells of the host as seen in 
transfusion-associated GVHD.27 Pancytopenia was rare in 
patients with cytogenetic relapse of CML and patients in 
remission after chemotherapy (Table 6). In both situations, 
hematopoiesis is maintained predominantly by donor type 
cells. In hematologic relapse of CML, most hemopoietic 
cells come from the leukemia and are of host type. Neverthe­
less, pancytopenia may not occur if hematopoietic stem cells 
of donor type are present in sufficient amounts. Evidence 
for a direct cytotoxic effect and the role of donor type stem 
cells comes from the infusion of marrow from the donor: 
infusion of donor marrow did correct myelosuppression in 
five patients without further immunosuppressive treatment.
Depletion of T cells from the previous marrow graft had 
a weak influence on the response of recurrent CML to lym­
phocyte transfusions, but complications of lymphocyte trans­
fusions were increased in all patient groups. Patients with 
T-cell -  depleted grafts developed myelosuppression and 
GVHD more frequently. In contrast to the results in animal
Mo. of Patients
Deaths with leukemia 47
Deaths without leukemia 17
GVHD 4
Pancytopenia/marrow aplasia 6
GVHD and cytopenia 4
Infection 1
Hemorrhage 1
Aspiration pneumonia 1
Total deaths 64
patients without any GVHD and myelosuppression was 45%
(13 of 29).
DISCUSSION
Therapeutic options for patients with recurrent leukemia 
after bone marrow transplantation are limited. Second mar­
row transplants from the same donor may be considered, but 
the mortality and treatment-related morbidity are high and
further recurrences are frequent.19'20 In CML, treatment with experiments, GVHD occurred in 60% of the patients. In
interferon-a may suppress the growth of the Philadelphia- 
positive clone,21,22 and prolong survival,23 but it is not cura­
tive. Another possibility is adoptive immunotherapy with 
donor lymphocytes in patients with established chimerism. 
Transfusions of lymphocytes from the marrow donor exert a 
strong graft-versus-leukeinia effect in patients with recurrent
mice28 and dogs7,29 donor lymphocytes can be transfused in 
large amounts without producing GVHD once chimerism 
and tolerance is established. Risk factors for de novo GVHD 
after lymphocyte transfusions are depletion of T cells from 
the previous marrow graft and treatment with interferon-a 
at the time of lymphocyte transfusions (Table 6). The effect
CML.8-15'24-26 The present study includes a relatively large of interferon-a on .de novo GVHD was most prominent in
group of patients with CML in various types of relapse and 
patients with recurrent PCV, AML, MDS, and ALL. It is 
unlikely that the results are influenced by selective reporting. 
Centers were asked to report all sequentially treated patients, 
and the results were discussed with each center. Reports on 
patients treated for recurrent myeloma and lymphoma were 
not of interest for this study. Response rates were not differ­
ent from those of single centers with larger series. The bene­
fits of adoptive immunotherapy with donor lymphocyte 
transfusions are greatest in patients with CML in cytogenetic 
and hematologic relapse. Transfusion of donor lymphocytes 
could induce remissions in PCV, AML, and MDS, but failed 
to induce remissions in relapsed ALL. Remissions were du­
rable in patients treated in cytogenetic and hematologic re­
lapse of CML: in responding patients the actuarial probabil­
ity of relapse 3 years after lymphocyte transfusion is less 
than 20% (Fig 3). In AML and MDS, duration of remission 
was longer, six patients are still in remission between 118 
and 855 days. In ALL and advanced stage CML, remissions 
were short and an effect of donor lymphocyte transfusion 
on the duration of chemotherapy-induced remissions could 
not be shown.
In CML, the response to adoptive immunotherapy was 
influenced favorably by the absence of acute or chronic 
GVHD after transplantation and the absence of blastic trans­
formation (Table 5). Due to recurrent CML, myeloid cells 
were either a mixture of host and donor-derived cells or host 
type exclusively.8 During the response to adoptive immuno-
patients with AML/MDS and ALL (P = .003) and not evi­
dent in CML/PCV. Interferon-a can upregulate the expres­
sion of class I antigens of the major histocompatibility com­
plex, activate natural killer (NK) cells and induce the 
secretion of other cytokines.30 Thus, it may stimulate GVHD 
in the absence of immunosuppressive treatment. In CML, 
stimulation of GVHD by interferon-a may be less effective, 
as CML cells often produce proinflammatory cytokines, such 
as tumor necrosis factor-a (TNF-a)31 and interleukin- \(3 (IL- 
1 / 3 f 2 that stimulate transfused T cells of the donor.
The correlation of de novo GVHD after lymphocyte trans­
fusion with T-cell depletion at marrow transplantation is
strong in AML/MDS and CML/PCV (P .04) and not
evident in ALL. However, the number of patients with ALL 
and T-cell depletion is small. Recipients of T-cell 
marrow grafts may survive despite histoincompatibility and 
may develop more frequently GVHD and myelosuppression 
after lymphocyte transfusions. Alternatively, a persisting T- 
cell deficiency in these patients may fail to maintain toler­
ance if challenged by transfused lymphocytes.
There is a close association of the GVL effect with either 
de novo GVHD or myelosuppression or both (Table 7), but 
there is also evidence for a GVL effect separate from myelo­
suppression and de novo GVHD. The risk factors for these 
complications differ from the pretreatment factors influenc­
ing the response and a GVL effect was observed in 13 of 
29 CML-patients (45%) without clinical evidence of GVHD 
or myelosuppression. In the latter patients, the response may
g r a f t -v e r s u s -l e u k e m ia 2047
_^ a^ e Pretreatment Factors influencing Response of Recurrent CML to Donor Lymphocyte Transfusions
Factor
Center
<s=6 pats, treated 
> 6  pats, treated 
Sex of patient 
M ale  
Female  
A g e of patient at BMT
36 yrs 
36 yrs
T yp e  of dondr
HLA-identical sibling 
Other 
Sfex of the donor 
m ale  
fem ale  
Stage at BMT 
Chronic phase 
Advanced phase 
T-cell depletion 
No  
Yes
A cute  or chronic GVHD after BMT 
No  
Yes
Remission duration 
< = 7 3 1  d 
>731  d 
Type of relapse 
Cytogenetic 
Hematologic 
Transformed 
No. of mononuclear cells per kg transfused 
<  = 1.0 x 108/kg 
1.1 -2.0 x 108/kg
2.1-3.0 x 10u/kg
3.1-4.0 x 10H/kg
4.1-5.0 x 10B/kg
5.1 x 10B/kg
Treatm ent with interferon-a 
Yes 
No
Abbreviation: NS, not significant. 
*  Transformed versus other type.
No. of Patients
Evaluable
37
43
48
32
40
40
70
10
55
25
63
13
46
30
31
45
40
40
17
50
8
12
8
21
12
13
11
60
19
Responding (%)
26 (70) 
33 (77)
37 (77) 
22 (69)
32 (80) 
27 (68)
50 (71) 
9 (90)
39 (71) 
20 (80)
50 (79) 
5 (38)
30 (65) 
25 (83)
26 (84) 
29 (64)
28 (70) 
31 (78)
14 (82) 
39 (78) 
1 ( 12)
8 (66) 
5 (60) 
16 (76) 
9 (75) 
11 (85) 
8 (73)
45 (75) 
13 (68)
Univariate Chi-Square Stepwise Logistic Regression
NS
NS
NS
NS
NS
P = .003 NS
P =  .07 NS
P = .055 P =  .03
NS
P =  .0001* P = .002
NS
NS
result from a reaction against leukemia-specific antigens or 
from  the GVH reaction against minor histocompatibility an­
tigens on leukemic cells. Some minor histocompatibility an­
tigens are predominantly expressed on hematopoietic pro­
genitor cells13 and may be expressed on progenitor cells of 
C M L  and AML/MDS. Minor histocompatibility antigens are 
presented by HLA class I and class II antigens. Decreased 
expression of HLA antigens and absence of costimulatory 
factors can permit leukemic cells to escape the GVL reaction. 
Potent costimulatory factors are proinflammatory cytokines 
(TN F-a, IL-I/3) and adhesion molecules (leukocyte function 
antigen 1 [LFA-1]). Increased serum levels of TNF-a after 
transplantation predict a high probability of GVHD.34 The
absence of LFA-1 on leukemia cells is associated with a 
lesser sensitivity to lysis by minor histocompatibility anti- 
gen-2 specific cytotoxic T lymphocytes.35 Interferons are po­
tent stimulators of monocytes and macrophages and inhibit 
the growth of CML cells by an unknown mechanism.30 It 
was hoped that treatment with interferon-a would control the 
growth of recurrent CML and stimulate the GVL reaction. 
Unfortunately, treatment with interferon-a did not improve 
die response significantly, but stimulated GVHD in acute 
leukemia.
It remains unclear why myeloid leukemias respond better 
to this form of adoptive immunotherapy than lymphoid leu­
kemia. In myeloid leukemias, in particular chronic myeloge-
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Table 6. Risk Factors For GVHD and Myelosuppression After Donor Lymphocyte Transfusions
Factor
No. of Patients
Univariate
Chi-square
Stepwise
Logistic
Regression
Analysis
No. of Patients
Stepwise 
Logistic 
Univariate Regression 
Chi-Square AnalysisEvaluable With GVHD {%) Evaluable With Myelosuppression (%)
Diagnosis
AML/MDS 26 13 (50) P = .04 NS 22 8 (36) NS
ALL 20 8 (40) 20 5 (25)
CML/PCV 81 55 (68) 80 28 (35)
Sex of the patient
male 73 44 (60) NS 70 29 (41) P = .04 NS
female 53 31 (58) 51 12 (25)
Age of the patient
<=35,5  yrs 65 38 (58) NS 63 19 (30) NS
>35.5 yrs 62 38 (61) 59 22 (37)
Sex of donor
Male 83 46 55 P — ,16 NS 79 25 (32) NS
Female 44 30 68 43 16 (37)
T-cell depletion at BMT
No 78 40 51 P =  .013 .0013 74 18 (24) P = .007 P = .03
Yes 49 36 73 48 25 (52)
Acute or chronic GVHD after
transplantation
Ves 71 44 (62) NS 55 20 (36) NS
No 56 32 (57) 67 21 (31)
Remission duration after
BMT
<=500 d 64 34(53) P =  .12 NS 59 22 (37) NS
>500 d 63 21 (33) 63 19 (30)
Chemotherapy
No 67 41 (61) P =  .1 NS 63 27 (43) P = .04 NS
Yes 54 25 (46) 53 13 (25)
Lymphocyte transfusion for
remission consolidation
No 107 64 (60) P = .04 NS 94 37 (39) P — .006 P = .04
Yes 18 6 (30) 18 1 (6)
Time from relapse to
lymphocyte transfusion
<  — 117 d 64 34 (53) P =  ,12 NS 60 18 (30) NS
>117 d 63 42 (67) 62 23 (37)
No. of mononuclear cells
transfused per kg
<=3,0  x 108/kg 67 40 (60) NS 66 18 (27) NS
>3.0 x 108/kg 57 29 (51) 56 22 (39)
IFN-treatment
No 47 21 (45) P « .01 P -  ,0009 44 15 (34) NS
Yes 78 53 (68) 77 25 (32)
Type of relapse (CML only)
Cytogenetic relapse 17 9 (53) NS 16 2 (12) P = .01
Hematologic relapse 53 26 (49) 51 25(49)
Abbreviation: NS, not significant.
nous leukemia, allogeneic antigen-presenting cells are of leu- cells of the host, because immunosuppressive treatment is 
kemia origin, and these cells may be particularly able to not given for prophylaxis of GVHD. The observed GVL 
stimulate and sustain the GVL reaction. effect in our patients may result from a cytotoxic T-cell 
A variety of different cells is transfused in the leukocyte response against leukemia-specific antigens or minor anti­
concentrates, but only T lymphocytes have sufficient longev- gens. In CML the bcrkibl fusion protein is a candidate for
ity to explain the results. Long-term survival of transfused 
T cells has been demonstrated with gene marking studies.-16
a leukemia-specific antigen. Proliferative T-cell responses 
against a peptide of this protein have been described,37 but
Transfused donor T cells may recognize antigens of the host leukemia-specific cytotoxicity has not been found. The GVL 
foreign to the donor and specifically react against leukemia effect may develop within 4 weeks after transfusion, but the
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Table 7, GVHD, Myeiosuppression, and Response of CML After
Donor Lymphocyte Transfusions
Grosshadern, University of Munich, Germany: 17; Division of He-
No. of 
Patients With 
Disease 
Response
GVHD Grade
^  —  o*^  z . Myelosuppressiont Studied Yes No
W II»! 19 17 2
’I* 17 16 1
H- 10 9 1
>**»►* » ¡i 29 13 16
Total 75 55 20
* P = .01 (stepwise log. regression), 
t  P = .02 (stepwise log. regression).
cytogenetic and molecular response may take several months
to occur. ’ Obviously the reaction needs time to build up a 
strong GVL effect. For stimulation costimulatory signals, 
expression of adhesion molecules, and secretion of proin- 
flammatory cytokines may be necessary for effective GVL
The benefits of the treatment of recurrent leukemia with 
the transfusion of donor lymphocytes are evident in CML, 
PCV, AML, and MDS. The risks are acceptable in view of 
the alternative second marrow transplantation. Toxicity may 
be improved by strict control and consequent treatment of 
GVHD, and the infusion of marrow or blood stem cells of 
the donor in cases with severe myeiosuppression. Further 
investigations of effectors and targets of GVL reactions and 
therapeutic attempts are necessary to improve the results in 
acute leukemia.
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